VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: VLAD who wrote (8727)	5/30/1998 5:40:00 PM
From: VLAD	Read Replies (2) of 23519

Perry, The article is from the Motley Fool and I will transcribe the part I was refering to: The magazine hyped the drug as "the son of Viagra" and quoted Jim McCamant, editor of a medical technology newsletter in Berkeley, CA, as saying ICOS IC351 drug "will be a potentially better product...because it has fewer side effects." This was news to the company itself, which has finished one small Phase 2 trial, is continuing a bigger Phase 2 trial of IC351, and has yet to release any clinical data on the drug. In other words Perry, all this hoopla over ICOS was based on one remark by a guy who just said something without any facts to support his statement. Even the company itself said it was news to them.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next